Source Fact: Financial Supervisory Service DART / 2024-11-08
Disclosure Type: Material Corporate Management Matters Related to Investment Decisions
💡 3-Second Summary
Alteogen has executed a massive US$ 300M (approx. KRW 419.7B, sales royalties excluded) technology export contract with global pharma Daiichi Sankyo to develop a subcutaneous (SC) formulation of the ADC cancer therapy Enhertu®, securing a non-refundable upfront payment of approx. KRW 28B within 30 days.
📊 1. [Summary of Core Disclosure Content and Major Figures]
- Contracting Party: Daiichi Sankyo (Based in Japan / Recent annual revenue: JPY 1,601,688M)
- Scope of Agreement: An exclusive license agreement for the development and commercialization of a subcutaneous (SC) injection formulation of Enhertu®, an antibody-drug conjugate (ADC) therapeutics, utilizing Alteogen’s Hybrozyme platform-based human hyaluronidase (ALT-B4).
- Total Contract Value (Maximum Potential Amount): US$ 300,000,000 (Approx. KRW 419,730,000,000) *Sales royalties are separate.
- Upfront Fee: US$ 20,000,000 (KRW 27,982,000,000) / Equivalent to 28.99% of the previous year’s consolidated annual revenue (KRW 96,523M).
- Milestones: US$ 280,000,000 (KRW 391,748,000,000)
- Payment & Execution Terms:
- The upfront fee is expected to be received within 30 days from the contract date (prior to December 08, 2024).
- Milestone payments will be received sequentially upon conducting clinical trials of the ALT-B4 applied product, and achieving regulatory approvals and sales targets in respective countries.
- Upfront, milestone, and royalty payments received under this agreement are entirely non-refundable.
- FX Conversion Rate: Converted using the Seoul Money Brokerage standard rate of 1,399.1 KRW/USD as of November 08, 2024.
- Contract Period: November 08, 2024, until the expiration of the corresponding royalty period.
- Risk Factors & Non-disclosure Clues:
- This is a conditional agreement contingent upon approvals from regulatory bodies (such as the US FDA and MFDS). Research termination or disapproval may trigger contract termination or a reduction in milestones.
- Detailed breakdowns of milestones and royalties will remain undisclosed until December 31, 2041, due to the counterparty’s trade secret request.
📈 2. [Expert View: What This Disclosure Means for Investors]
This announcement indicates a significant mid-to-long-term catalyst directly strengthening Alteogen’s business fundamental, as its core proprietary platform ‘ALT-B4’ has been adopted by Enhertu, one of the world’s leading blockbuster oncology drugs. Securing a non-refundable upfront payment of KRW 28B alone covers roughly 29% of its entire annual revenue from last year, which could provide a highly favorable impact on short-term liquidity.
However, investors should carefully weigh the explicit risk factors noted in the text. Except for the upfront payment, approximately 93% (US$ 280M) of the total contract value is structured as conditional milestones tied to successful clinical developments and regulatory clearances across nations. Since failure in clinical trials or regulatory rejections may lead to contract cancellation or milestone losses, a prudent approach requires investors to treat this as a long-term development process and continuously monitor Daiichi Sankyo’s upcoming clinical timelines for the Enhertu SC formulation.
📝 Editor’s Comment (by K-STOCK Editor)
Enhertu®, a global megahit block-buster in the oncology arena, has officially tapped Alteogen’s ALT-B4 platform! This exclusive licensing deal with Daiichi Sankyo re-emphasizes Alteogen’s peerless competitive edge in the subcutaneous (SC) conversion space. A guaranteed, non-refundable cash pile of KRW 28B will hit the bank within 30 days, and the running royalties from future net sales will keep rolling in completely on top of the US$ 300M headline figure. While the conditional nature of bio-tech milestone agreements means the pipeline risks still exist until final FDA nods, pairing up with a best-in-class cancer therapy is an absolutely massive development that is bound to supercharge market sentiment.
📢 Disclaimer and Source Information
Source: This content has been structured and newly written based on the official data submitted to the Electronic Disclosure System (DART) of the Financial Supervisory Service.
Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!